SAN DIEGO, Feb. 9 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the 21st Annual Roth OC Growth Stock Conference on Monday, February 16, 2009 at 1:00 p.m. PST (4:00 p.m. EST). The conference is being held at The Ritz-Carlton, Laguna Niguel.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical programs: ANA598 and ANA773 in hepatitis C and ANA773 in cancer.

The presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through March 2, 2009.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

SafeHarbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines in the areas of hepat'/>"/>

(Date:3/2/2015)... -- Neurotechnology , a provider of high-precision biometric, robotics ... Development Kit (SDK). The SentiGaze algorithm enables designers ... to track eye movements and generate heatmaps based on ... be used for applications such as analysis of websites ... can also be used to develop interfaces for a ...

(Date:2/24/2015)... Feb. 24, 2015 Research and Markets ... of the "Global 2D Gesture Recognition Market ... The analysts forecast the Global 2D Gesture ... 32.12% over the period 2014-2019 The ... sectors is one of the major trends in ...

... photosynthesis, it's good to think "outside the bun." , That's ... Arts & Sciences at Washington University in St. Louis, did ... his collaborators at Lawrence Berkeley National Laboratory and the University ... taco shell protein. , Taco shell protein ...

... "backup" brain region springs into action to compensate for disruption ... finding offers new insight into how the brains of stroke ... of movement. , Jacinta O'Shea and colleagues at the University ... issue of the journal Neuron, published by Cell Press. ...

... The antiviral drug peramivir might offer humans significant protection ... according to results of mouse studies conducted by investigators ... Peramivir, an antiviral drug, blocks the ability of influenza ... the release of new virus particles and their spread ...

(Date:3/3/2015)... SAN CARLOS, Calif. , March 3, 2015 /PRNewswire/ ... with expertise in drug-disease modeling and simulation research, today ... during the 2015 American Society for Clinical Pharmacology and ... March 3-7 2015. Logo - ... and Rosa will present a poster describing a ...

(Date:3/3/2015)... 2015 Research and Markets ( ... PharmaBiotech,s new report "Personalized Medicine - Scientific ... , The aim of personalized medicine ... drug to the right patient and, in some ... a patient according to his/her genotype. This report ...

(Date:3/3/2015)... FRANCISCO , March 3, 2015 Johnson & ... @ South San Francisco (JLABS @SSF), ... Boulevard, South San Francisco, Calif. ... accommodate up to 50 startups from across the healthcare ... health. The first resident startups have ...

... May 13 A guide to BRCA1 and ... resource is designed to equip physicians and other healthcare professionals who are ... the complexities of BRCA1/2 gene testing. , ... According to the American Cancer Society, ...